MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Paratek Pharmaceuticals Company Profile (NASDAQ:PRTK)

Consensus Ratings for Paratek Pharmaceuticals (NASDAQ:PRTK) (?)
Ratings Breakdown: 8 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $37.88 (186.50% upside)

Analysts' Ratings History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Show:
DateFirmActionRatingPrice TargetActions
6/17/2016BTIG ResearchReiterated RatingBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016Robert W. BairdReiterated RatingOutperform$30.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016Cantor FitzgeraldReiterated RatingBuy$27.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016Ladenburg ThalmannBoost Price TargetBuy$46.00 -> $52.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016HC WainwrightBoost Price TargetBuy$31.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/15/2016Leerink SwannReiterated RatingBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/13/2015GuggenheimReiterated RatingBuy$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/22/2015GabelliInitiated CoverageBuy$34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Paratek Pharmaceuticals (NASDAQ:PRTK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/2/2016($1.25)($1.77)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q4($1.18)($1.20)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.91)($1.33)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.75)($0.94)$3.62 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/18/2015Q1($2.16)($0.74)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2014($0.18)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q413($0.21)($0.29)$0.50 million$0.32 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2013Q1 2013($0.42)($0.56)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2012Q312$0.06$0.25$8.37 million$10.44 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($1.29)($1.29)($1.29)
Q2 20162($1.64)($1.32)($1.48)
Q3 20162($1.38)($1.36)($1.37)
Q4 20162($1.39)($1.28)($1.34)
(Data provided by Zacks Investment Research)
Dividend History for Paratek Pharmaceuticals (NASDAQ:PRTK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
5/14/2014special$1.336/4/20145/26/20146/3/2014Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)
Insider Trading History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/23/2016Michael BighamCEOBuy20,000$13.45$269,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Evan LohCMOBuy2,300$16.87$38,801.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2015Hbm Healthcare Investments (CaMajor ShareholderSell20,580$30.75$632,835.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/13/2013Roumell Asset Management, Llcmajor shareholderSell1,470$3.54$5,203.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2013Roumell Asset Management, Llcmajor shareholderSell10,490$3.55$37,239.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2013Roumell Asset Management, Llcmajor shareholderSell8,710$3.54$30,833.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2013Roumell Asset Management, Llcmajor shareholderSell7,120$3.50$24,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013Roumell Asset Management, Llcmajor shareholderSell10,040$3.57$35,842.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2013Roumell Asset Management, Llcmajor shareholderSell7,190$3.53$25,380.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2013Roumell Asset Management, Llcmajor shareholderSell4,960$3.61$17,905.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2013Roumell Asset Management, LlcMajor ShareholderSell7,020$3.69$25,903.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Paratek Pharmaceuticals (NASDAQ:PRTK)
DateHeadline
06/28/16 10:47 AMTuesday 6/28 Insider Buying Report: LNG, PRTK
06/27/16 05:55 PMParatek Pharmaceuticals : Announces Pricing of Public Offering of 4,250,000 Shares of Common Stock
06/27/16 05:55 PMParatek Announces Closing of Common Stock Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
06/26/16 05:01 PMLadenburg Thalmann Maintains Paratek Pharmaceuticals Inc to Buy with Price Target $52.00 - Trade Calls
06/23/16 08:35 AMTwo Movers inside Analysts Radar: Bristol-Myers Squibb Company (NYSE:BMY) , Paratek Pharmaceuticals, Inc ... - Street Updates
06/23/16 08:35 AMParatek Pharmaceuticals, Inc. (NasdaqGM:PRTK) Stock Momentum Hits Weakness - CML News
06/22/16 05:53 PMParatek Announces Pricing of Public Offering of 4,250,000 Shares of Common Stock
06/22/16 04:07 PMPARATEK PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events -
06/22/16 10:40 AMSizzling Stocks Alert - Whiting Petroleum, (NYSE:WLL), Paratek Pharmaceuticals, (NASDAQ:PRTK) - Hot Stocks Point
06/22/16 10:40 AMParatek Pharmaceuticals (PRTK) Prices 4.25M Common Stock Offering at $13/Share - StreetInsider.com
06/22/16 10:40 AMParatek Pharmaceuticals (NASDAQ:PRTK) Analyst Rating Consensus - Trade Calls
06/21/16 05:30 PMParatek Pharmaceuticals : Announces Proposed Public Offering of Common Stock
06/21/16 10:17 AMParatek Announces Proposed Public Offering of Common Stock
06/20/16 05:42 PMParatek Pharmaceuticals (PRTK) Expects to Present Omadacycline Phase 1b Data in Q416 - StreetInsider.com
06/20/16 07:19 AMParatek Announces that Omadacycline Met All Primary and Secondary Efficacy Outcomes Designated by FDA and EMA in a Phase 3 Study in Acute Bacterial Skin Infections; Omadacycline was Generally Safe and Well-Tolerated - [at noodls] - Company to host a webcast and conference call for investors at 4:30 pm EDT to review top-line results BOSTON, June 16, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announces today ...
06/20/16 07:00 AMParatek Accelerates Timing for Projected Reporting of Top-Line Data for Omadacycline Phase 1b Urinary Tract Infection Study - [GlobeNewswire] - BOSTON, June 20, 2016-- Paratek Pharmaceuticals, Inc. announced today that it projects its ongoing phase 1 b clinical study evaluating omadacycline in the treatment of uncomplicated urinary tract infections ...
06/19/16 09:46 AMParatek Spikes On Study Results
06/19/16 09:46 AMParatek Pharmaceuticals Inc. (PRTK) Is Rising On Phase 3 Study News
06/18/16 10:05 AMHome Biotech Stocks Paratek Pharmaceuticals, Inc. | $PRTK Stock | Shares Spike Up On Positive... - TickerTV News (press release)
06/17/16 05:44 PMBuzz Stocks: Smith & Wesson Holding Corp, Paratek Pharmaceuticals Inc, and Lumber Liquidators Holdings Inc - Schaeffers Research (blog)
06/17/16 11:19 AMParatek Pharmaceuticals Announces Positive Phase 3 Results for its Antibiotic Omadacyline - [at noodls] - 8914b644-3dc3-4314-a576-1bfc0f8e797a.pdf Media Release Zug, 17 June 2016 Paratek Pharmaceuticals (Nasdaq: PRTK), a listed company in the portfolio of HBM Healthcare Investments, yesterday announced that ...
06/17/16 08:42 AMBuzz Stocks: Smith & Wesson Holding Corp, Paratek Pharmaceuticals Inc, and Lumber Liquidators Holdings Inc
06/17/16 08:42 AMParatek Pharmaceuticals Inc. (PRTK) Is Climbing On Phase 3 Results
06/17/16 08:42 AMParatek Pharmaceuticals (PRTK) Announces Omadacycline Phase 3 Met All Primary, Secondary Endpoints in ABSSSI
06/16/16 06:11 PMParatek Pharmaceuticals Inc. (PRTK) Is Climbing On Phase 3 Results - RTT News
06/13/16 03:29 PMParatek Pharmaceuticals, Inc. Announces Participation in JMP Securities Life Sciences Conference - [at noodls] - BOSTON, June 01, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that its President and Chief Medical Officer, Evan Loh, MD, will participate in the JMP Securities ...
06/13/16 03:01 PMParatek to Present Omadacycline Microbiologic, Pharmacokinetic and Clinical Data at ASM Microbe 2016 - [GlobeNewswire] - -Biofilm, post-antibiotic effects, microbiologic surveillance and omadacycline in vitro activity against select pathogens to be presented. -Clinical PK and Modelling Strategies for omadacycline to be presented. ...
06/09/16 03:41 PMPARATEK PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/03/16 06:30 PMHow Analysts Rated Paratek Pharmaceuticals Inc (NASDAQ:PRTK) Last Week? - HNN
06/02/16 06:22 PMBroker Watchlist: Paratek Pharmaceuticals, Inc. (PRTK) - Share Trading News - Broker Watchlist: Paratek Pharmaceuticals, Inc. (PRTK)Share Trading News11/03/2014 – Ladenburg Thalmann began new coverage on Paratek Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 26 price target on the stock. The share price of Paratek Pharmaceuticals, Inc. (PRTK) was up +0.12% during ...and more »
06/02/16 12:03 PMParatek Pharmaceuticals, Inc. :PRTK-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
06/01/16 08:50 AMParatek Pharmaceuticals, Inc. (PRTK) Updated Price Targets - FTSE News - Paratek Pharmaceuticals, Inc. (PRTK) Updated Price TargetsFTSE News02/29/2016 – H.C. Wainwright began new coverage on Paratek Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 32 price target on the stock. 01/08/2016 – Paratek Pharmaceuticals, Inc. had its “outperform” rating reiterated by ...Paratek Pharmaceuticals Inc (PRTK) Earns “Buy” Rating from Cantor FitzgeraldLet Me Know About ThisRecently Changed Price Targets On Paratek Pharmaceuticals, Inc. (PRTK)Risers & FallersParatek Pharmaceuticals, Inc. Announces Participation in JMP Securities Life Sciences ConferencePharmiWeb.com (press release)all 4 news articles »
05/31/16 09:59 AMStock Review and Earnings Check on Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - HNN - Stock Review and Earnings Check on Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Paratek Pharmaceuticals, Inc.and more »
05/30/16 02:01 PMParatek Pharmaceuticals Incorporated (NASDAQ:PRTK) Shorted Shares Increased 31.13% After Market Selling - HNN - Paratek Pharmaceuticals Incorporated (NASDAQ:PRTK) Shorted Shares Increased 31.13% After Market SellingHNNThe short interest to Paratek Pharmaceuticals Incorporated's float is 5.04%. The stock increased 0.33% or $0.05 on May 27, hitting $15.34. About 83,132 shares traded hands or 2.03% up from the average. Paratek Pharmaceuticals Inc (NASDAQ:PRTK) has ...
05/29/16 12:44 PMExplaining The Dreaded Superbug Found In Pennsylvania Woman - Medicines Co (MDCO.O); and Paratek Pharmaceuticals Inc (PRTK.O). According to CNN, one of the most concerning things about the superbug is that it could "jump" to other bacteria that is resistant to Colistin, or mcr-1, and create an even larger ...
05/26/16 12:13 PMStock Rating Review for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Wall Street Hints and News - Stock Rating Review for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1 on shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus ...and more »
05/26/16 12:13 PMParatek Pharmaceuticals Incorporated (NASDAQ:PRTK) Shorted Shares Decreased By 37.44% - Wall Street Hints and News - Paratek Pharmaceuticals Incorporated (NASDAQ:PRTK) Shorted Shares Decreased By 37.44%Wall Street Hints and NewsThe short interest to Paratek Pharmaceuticals Incorporated's float is 3.99%. The stock increased 0.06% or $0.01 during the last trading session, hitting $15.45. About 52,810 shares traded hands. Paratek Pharmaceuticals Inc (NASDAQ:PRTK) has declined ...
05/16/16 05:59 PMPARATEK PHARMACEUTICALS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements -
05/13/16 04:46 AMCoverage initiated on Paratek Pharma by Robert W. Baird -
05/10/16 03:18 PMParatek Pharmaceuticals, Inc. Reports First Quarter 2016 Financial and Operating Results - [at noodls] - Completed enrollment in Phase 3 ABSSSI study Faster-than-projected enrollment in Phase 3 CABP study Initiated dosing in Phase 1b UTI study Conference call scheduled for 8:30 a.m. EDT on May 3, 2016 BOSTON, ...
05/10/16 03:01 PMParatek Receives FDA Affirmation for Design of Proposed Omadacycline Oral-Only Skin Infection Phase 3 Study: Opportunity to Accelerate Access to Broader Oral-Only Markets - [GlobeNewswire] - FDA Affirms Chosen Comparator, Primary Endpoint for Phase 3 Study Study, if Conducted, Would Initiate Following the Reporting of Top-Line Data from IV-to-Oral ABSSSI Phase 3 Study Potential to Include ...
05/02/16 04:11 PMParatek reports 1Q loss -
05/02/16 04:10 PMParatek Initiates Phase 1b Study of Omadacycline in Urinary Tract Infection - [at noodls] - BOSTON, May 02, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today the dosing of the first patient in its Phase 1b study of omadacycline in patients with Urinary Tract ...
05/02/16 04:10 PMParatek Pharmaceuticals to Report First Quarter 2016 Financial Results on May 3, 2016 - [at noodls] - BOSTON, April 25, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline ...
04/25/16 09:24 AMParatek Presents Data from Omadacycline Clinical Development Program at ECCMID - [at noodls] - Pooled analysis from Phase 2 and truncated Phase 3 studies demonstrates comparable safety and efficacy profiles for omadacycline compared with linezolid Single dose randomized trial demonstrates that omadacycline ...
04/11/16 09:40 AMParatek presents new trial data for antibiotic as late-stage trials continue -
02/26/16 12:08 PMWhat Is Mean Rating On Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)? - Stocks Daily - What Is Mean Rating On Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)?Stocks DailyZacks Group, a notable entity in the industry, designed a poll of sell-side experts, which revealed that Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has a rating of 1. This score is given on a 1 to 5 scale, which is also termed as sliding scale ...Brokerage Analyst Buys: Marketo, Inc. (NASDAQ:MKTO), Bio-Techne Corp (NASDAQ:TECH), Calavo Growers, Inc ...RiversideGazette.comall 2 news articles »
02/23/16 06:00 AMParatek Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2015 Financial and Operating Results - [GlobeNewswire] - BOSTON, Feb. 23, 2016-- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today reported ...
02/23/16 05:21 AMPARATEK PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -
02/16/16 07:00 AMParatek Pharmaceuticals to Report Fourth Quarter 2015 Financial Results on February 23, 2016 - [GlobeNewswire] - BOSTON, Feb. 16, 2016-- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced ...
About Paratek Pharmaceuticals

Paratek Pharmaceuticals logoParatek Pharmaceuticals, Inc. (Paratek), formerly Transcept Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek's antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). The Company's sarecycline is a Phase III antibacterial product candidate and was previously known as WC3035. Sarecycline is designed for use in the treatment of acne and rosacea. The Company's other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: PRTK
  • CUSIP: 89354M10
Key Metrics:
  • Previous Close: $12.52
  • 50 Day Moving Average: $14.882
  • 200 Day Moving Average: $15.295
  • P/E Ratio: N/A
  • P/E Growth: 0.000
  • Market Cap: $235.14M
  • Current Quarter EPS Consensus Estimate: $N/A EPS
Additional Links:
Paratek Pharmaceuticals (NASDAQ:PRTK) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha